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OBJECTIVE—Type 2 diabetes is associated with increased risks of several types of cancer;
however, its relationship to renal cell cancer remains unclear.
RESEARCH DESIGN AND METHODS—A total of 118,177 women aged 30 to 55 years
at baseline (1976) were followed up through 2008 in the Nurses’ Health Study. Self-reports of
physician-diagnosed diabetes were collected at baseline and updated biennially. Hazard ratios
(HRs) were calculated using Cox proportional hazards models with adjustment for age, BMI,
hypertension, smoking, and parity.
RESULTS—During 32 years of follow-up (3,531,170 person-years), 16,819 cases of type 2
diabetesand330casesofpathology-conﬁrmedincidentrenalcellcancerweredocumented.After
multivariate adjustment, type 2 diabetes was signiﬁcantly associated with an increased risk of
renal cell cancer (HR 1.60 [95% CI 1.19–2.17]). These associations were consistent across
different strata of BMI, smoking, and hypertension (Pinteraction $ 0.32). The risk of renal cell
cancer increased with an increasing number of comorbidities, including obesity, hypertension,
and type 2 diabetes (Ptrend , 0.001). When compared with women without any comorbidity,
women who had all three conditions had a HR of 4.13 (2.76–6.18) for renal cell cancer.
CONCLUSIONS—Type2diabetesisindependentlyassociatedwithanincreasedriskofrenal
cell cancer in women. In addition, comorbidity of obesity, hypertension, and type 2 diabetes
substantially elevates the risk of renal cell cancer.
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T
he prevalence of type 2 diabetes
is increasing worldwide. From
1980 through 2007, the number of
Americans with diabetes more than tri-
pled from 5.6 million to 17.4 million (1).
Recent epidemiologic evidence suggests
that type 2 diabetes is associated with an
increased risk of cancer of colon, breast,
liver, endometrium, and pancreas (2–5).
Possible mechanisms for these associations
includehyperinsulinemia,increasedIGF-I,
hyperglycemia, and inﬂammatory cyto-
kines in diabetes (2,4,5).
Renal cell cancer accounts for 85% of
kidney cancer, which is the 15th most
common cancer in the world (6). Renal
cell cancer is mainly a disease of high-
income countries, and populations in
North America and parts of Europe have
10to15timeshigherprevalencethanAsian
and African populations (6). Nonetheless,
the rates of renal cell cancer are increasing
worldwide (6), and this global increase is
not fully explained by improvements in
detection of tumor (7). The large geo-
graphic variation in renal cell cancer rates
suggests that westernization may contrib-
ute to its etiology. The Western diet and
physical inactivity often result in obesity
and insulin resistance, consequently lead-
ing to metabolic syndrome and type 2 di-
abetes. Obesity and hypertension are the
most established risk factors for renal cell
cancer (4,8,9), and both factors are linked
to type 2 diabetes through insulin resis-
tance and metabolic syndrome.
Therefore, we hypothesized that type
2 diabetes would be associated with an
increased risk of renal cell cancer and
interact synergistically with obesity and/
or hypertension due to the common un-
derlying mechanism of insulin resistance.
Deﬁning this association is important
given the rising global epidemic of type
2 diabetes and also, to some extent, renal
cell cancer, but evidence from previous
studies has been unclear. Most investiga-
tions were case-control studies (8,10,11)
although a few wereprospective(9,12,13).
In this study, we prospectively evaluated
the association between type 2 diabetes
and subsequent renal cell cancer risk in
the Nurses’ Health Study.
RESEARCH DESIGN AND
METHODS
Study population
The Nurses’ Health Study cohort was es-
tablished in 1976 when 121,700 female
registered nurses aged 30 to 55 years
returned a mailed questionnaire about
medical history and various risk factors
for chronic disease. Follow-up question-
naires were sent every 2 years to update
information on lifestyle factors and newly
diagnosed diseases. Deaths in the cohort
were identiﬁed by reports from family
members in response to the follow-up
questionnaires and from the National
Death Index. In this study, women who
reported renal cell cancer or any other
cancer (except for nonmelanoma skin
cancer) before baseline were excluded
from analyses. The follow-up rate in this
study population was 98%. The Nurses’
Health Study was approved by the insti-
tutional review board of Brigham and
Women’s Hospital (Boston, MA).
Assessment of diabetes
On the baseline and subsequent biennial
questionnaires, we asked the participants
ifand when they hadever been diagnosed
with diabetes by a physician. All women
who reported a diagnosis were mailed a
supplementary questionnaire requesting
additional information on symptoms,
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ORIGINAL ARTICLEdiagnostic tests, and treatments. Partici-
pants were considered to have type 2 dia-
betes if they met the National Diabetes
Data Group criteria (14), were diagnosed
at age 30 years or over, and did not meet
the criteria for type 1 (insulin-dependent
and ketosis-prone) diabetes. Women
whose dates of diagnosis were unknown
(n = 113) were excluded from analyses.
We included women who had been diag-
nosed with type 2 diabetes either at base-
line or during the follow-up period.
The validity of self-reported diabetes
wasinvestigatedinarandomsampleof62
women in this cohort. The diagnoses of
type 2 diabetes were conﬁrmed by med-
ical record review for 98.4% of the
women (15). In addition, another sub-
study assessing the prevalence of undiag-
nosed diabetes suggested a very low rate
(0.5%) of false-negative results (15).
Ascertainment of renal cell cancer
Self-reported information on newly di-
agnosed kidney cancer was obtained on
each biennial questionnaire. Participants
(or next of kin on behalf of decedents)
whoreportedadiagnosisofkidneycancer
were asked for permission to access med-
ical records. Physicians blinded to partic-
ipants’ information reviewed medical
records. Women whose diagnoses of kid-
ney cancerwere not conﬁrmedby pathol-
ogy reports were excluded from analyses
(n = 115). Based on the World Health Or-
ganization classiﬁcation (16), cases of
renal cell cancer included clear cell,
papillary, chromophobe, collecting duct
carcinoma, and renal cell carcinoma un-
classiﬁed. Renal pelvis or ureter cancer
wasnotincludedduetoalimitednumber
o fc a s e si nt h i sc o h o r t .
Assessment of other risk factors
Information on body weight, smoking,
history of hypertension, and parity has
been updated every 2 years since 1976.
BMI (in kg/m
2) was calculated using
height from 1976 and updated weight.
Self-reported and measured weights
were highly correlated (r = 0.97) in a val-
idation study (17). For past and current
smokers, pack-years of smoking werecal-
culated by multiplying the duration and
dose of smoking. Physician-diagnosed
hypertension was self-reported, and its
reliability was reported by a validation
study (18). Parity was updated until
1996, when few childbirths were reported
inthiscohort.Information onalcoholcon-
sumption, fruit and vegetable intake, and
physical activity was obtained from 1980.
Statistical analysis
Participants were followed up prospec-
tively for the diagnosis of type 2 diabetes
and incident renal cell cancer from 1976
to 2008. Person-years of follow-up were
calculated from the date of return of the
1976 questionnaire to the date of renal
cell cancer diagnosis, the date of death
from any cause, or the end of follow-up
(31 May 2008), whichever came ﬁrst. We
entered status of type 2 diabetes in the
model as a time-dependent variable al-
lowingthestatustochangeduringfollow-
up upon a new diagnosis. For women
who had diabetes at baseline, person-years
as diabetic were calculated fromthe begin-
ning of the study (1976); women who
developed diabetes during follow-up con-
tributed person-years as nondiabetic while
they were free of diabetes and as diabetic
from the dates of diagnosis.
Cox proportional hazards regression
models were used to calculate the hazard
ratios (HRs) with 95% CIs. The propor-
tionality assumption of Cox models was
not violated. To control as ﬁnely as
possible for confounding by age, calendar
time, and any possible two-way interac-
tions between these two time scales, we
stratiﬁed the analysis jointly by age in
months at start of follow-up and calendar
year of the current questionnaire cycle. In
the multivariate models, we additionally
adjusted for potential confounders, in-
cluding BMI (continuous), smoking sta-
tus (never, past, current) and pack-years
(continuous), history of hypertension
(yes, no), and parity (nulliparous, 1–2,
3,4,$5children).Inasecondaryanalysis
beginningatthefollow-upfrom1980,we
tested whether inclusion of additional
covariates (race [white, nonwhite], alco-
hol consumption, fruit and vegetable in-
take, and physical activity) would alter
the results.
Because insulin levels may vary at
different stages of diabetes, we evaluated
the risk of renal cell cancer depending on
time since diagnosis of diabetes. Time
since diagnosis was calculated from the
dateofdiabetesdiagnosisandcategorized
into 5-year intervals. Linear trend of renal
cell cancer risk was tested among diabetic
women using time since diagnosis as a
continuousterm(inmonth)inthemodel.
We conducted stratiﬁed analyses by
levels of BMI (,30, $30 kg/m
2), smok-
ing status (never, ever), and history of hy-
pertension (no, yes) because these are
known risk factors of renal cell cancer
and may be related to type 2 diabetes
through insulin resistance and metabolic
syndrome. Using the likelihood ratio test,
the model including the interaction term
for variables of interest was compared
with the model with the main effect
only. In addition, the combined effects
of obesity (BMI $30 kg/m
2), hyperten-
sion, and type 2 diabetes on the risk of
renal cell cancer were evaluated. Accord-
ing to the number of combined condi-
tions, participants were categorized into
four subgroups (zero, one, two, or three
conditions). Linear trend was examined
by treating the number of combined con-
ditions as a continuous term.
Finally, we assessed public health bur-
denofprevalentobesity,hypertension,and
type 2 diabetes by calculating population-
attributable risk proportions.
Statistical tests were performed using
SAS statistical software version 9.1 (SAS
Table 1—Age-standardized characteristics of study participants in 1990*
Characteristic No diabetes Type 2 diabetes
Women (n) 107,714 6,424
Age, mean (years) 56.8 57.0
Duration of type 2 diabetes, mean (years) — 9.3
White (%) 96.9 94.3
BMI, mean (kg/m
2) 25.5 30.5
History of hypertension (%) 28.8 63.4
Current smokers (%) 17.6 15.7
Past smokers (%) 37.9 38.7
Pack-years of smoking, mean† 24.2 25.7
Alcohol intake (g/day) 6.2 3.4
Fruit intake (g/day) 2.2 2.3
Vegetable intake (g/day) 2.8 2.8
Physical activity, mean (METs) 15.4 12.2
Parity, mean (no. of children)‡ 3.0 3.0
*Except for the data on mean of age, all data shown are age-standardized to the age distribution of study
population; †among current or past smokers only; ‡among parous women only.
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two-tailed; P , 0.05 was considered sta-
tistically signiﬁcant.
RESULTS—During 32 years of follow-
up of 118,177 women (3,531,170 per-
son-years), we documented 16,819 cases
of type 2 diabetes (1,638 at baseline and
15,181 during follow-up) and 330 cases
of incident renal cell cancer. Table 1 pres-
ents characteristics ofthe study population
in 1990 (the midpoint of the follow-up
period was chosen to best represent the
overallfollow-up).Womenwhoreported
type 2 diabetes had a substantially higher
BMIandhistoryofhypertensioncompared
with nondiabetic women.
Type 2 diabetes was associated with a
signiﬁcantly increased risk of renal cell
cancer (Table 2). The age-adjusted HR
was 2.22 (95% CI 1.67–2.95) for diabetic
w o m e nc o m p a r e dw i t hn o n d i a b e t i c
women. After additional adjustment for
BMI and hypertension, the HR was atten-
uated to 1.61 (1.19–2.18). Further ad-
justment for smoking status, pack-years
of smoking, and parity did not materially
change the HR (1.60 [1.19–2.17]). Sec-
ondary analyses with additional adjust-
ment for race, alcohol consumption,
fruit and vegetable intake, and physical
activity showed a similar HR of 1.61
(1.19–2.19). In all of the multivariate
models, BMI and history of hypertension
as well as type 2 diabetes were signiﬁ-
cantly associated with the risk of renal
cell cancer. The results for either clear
cell (n = 224) or nonclear cell (n = 106)
were similar to the results for overall
renal cell cancer (1.84 [1.30–2.60] for
clear cell; 1.72 [1.01–2.96] for nonclear
cell). When compared with nondiabetic
women, diabetic women on any diabetic
medicationstatus(none,oralmedications
only, and insulin with or without oral
medications) experienced higher HRs
for renal cell cancer (1.81 [1.20–2.75],
1.51 [1.00–2.28], 1.29 [0.57–2.95], re-
spectively). To exclude the possible cases
ofrenalcellcancerprecedingdiabetes,we
dropped ﬁve cases of cancer occurring
within 2 years of diabetes diagnoses, and
the increased risk was still signiﬁcant
(1.48 [1.08–2.02]).
The increasedHRsofrenalcellcancer
were observed up to 15 years of duration
of diabetes, and then the HR diminished
(Ptrend = 0.01; Table 3). Diabetic women
whose duration of diabetes was 5–10
years had the strongest HR of 2.07 (95%
CI 1.28–3.36). When the analysis was
conﬁned to the incident diabetes during
follow-upwith256casesofrenalcellcan-
cer, similar association was observed
( d a t an o ts h o w n ) .D i a b e t i cw o m e nh a d
consistently higher cumulative incidence
of renal cell cancer than nondiabetic
women, and the cumulative incidence
curves did not cross over the follow-up
period (Supplementary Fig. 1).
In stratiﬁed analyses by levels of
BMI,historyofhypertension,andsmok-
ing status, the positive associations be-
tween type2 diabetesandrenalcellcancer
were consistent across different strata
(Pinteraction $ 0.32).
In addition, combined effects of obe-
sity, hypertension, and type 2 diabetes on
the risk of renal cell cancer were observed
(Fig.1).Womenwhohadboth obesity and
diabetes hada signiﬁcantlyincreasedrisk of
renal cell cancer than obese nondiabetic
women (HR 1.92 [95% CI 1.26–2.91]).
Compared with nonobese nondiabetic
women, obese diabetic women had a HR
of 2.34 (1.62–3.39); however, obese non-
diabetic women did not show a signiﬁ-
cantly increased HR (1.22 [0.91–1.64]).
Exclusion of women with BMI ,18.5
kg/m
2 did not alter the association (data
not shown). Similarly, women who had
bothhypertensionanddiabeteshadahigher
HR of 1.71 (1.23–2.36) compared with
women who had hypertension but no dia-
betes. When we considered the conditions
ofobesity,hypertension,andtype2diabetes
together, a higher number of comorbid
conditions increased the risk of renal cell
cancer with signiﬁcant linear trend (Ptrend ,
0.001). Women who had all three con-
ditions showed a strikingly elevated risk
than women without any comorbidity
(HR 4.13 [95% CI 2.76–6.18]).
Obesity, hypertension, and type 2
diabetes accounted for 31% (popula-
tion-attributable risk) of incident renal
cell cancer among this population of
women.
CONCLUSIONS—In this large pro-
spective study of women, type 2 diabetes
was signiﬁcantly associated with an in-
creased risk of renal cell cancer. Moreover,
the risk was dose dependently elevated
with an increasing number of comorbid
metabolic conditions.
Priorepidemiologicstudiessuggested
some but inconclusive evidence for the
Table 2—History of type 2 diabetes and HRs of renal cell cancer among participants in the Nurses’ Health Study, 1976–2008
No. of RCC
cases
Person-
years
Age-adjusted
HR [95% CI]
Multivariate
HR [95% CI]*
Multivariate
HR [95% CI]†
History of type 2 diabetes
No 270 3,303,773 1 (referent) 1 (referent) 1 (referent)
Yes 60 227,397 2.22 [1.67–2.95] 1.61 [1.19–2.18] 1.60 [1.19–2.17]
RCC, renal cell cancer. *Adjusted for age in months, BMI (kg/m
2, continuous), and hypertension (yes, no); †adjusted for everything in *, and smoking status (never,
past, current), pack-years of smoking (continuous), and parity (nulliparous, 1–2, 3, 4, $5 children).
Table 3—Duration of type 2 diabetes and HRs of renal cell cancer
No. of RCC
cases Person-years
Age-adjusted
HR [95% CI]
Multivariate
HR [95% CI]*
Duration of type 2 diabetes
No type 2 diabetes 270 3,303,773 1 (referent) 1 (referent)
#5y e a r s 2 1 7 5 , 1 5 1 2 . 4 6[ 1 . 5 7 –3.85] 1.79 [1.13–2.83]
5.1–10 years 19 54,610 2.96 [1.85–4.74] 2.07 [1.28–3.36]
10.1–15 years 12 38,954 2.66 [1.48–4.76] 1.92 [1.06–3.47]
.15 years 8 58,682 1.04 [0.51–2.11] 0.78 [0.38–1.59]
Ptrend† 0.02 0.01
RCC, renal cell cancer. *Adjusted for age in months, BMI (kg/m
2, continuous), hypertension (yes, no),
smokingstatus(never,past,current),pack-yearsofsmoking(continuous),andparity(nulliparous,1–2,3,4,
$5children);†calculatedamongwomenwithtype2diabetesusingtimesincediagnosisofdiabetes(months,
continuous).
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Type 2 diabetes and renal cell cancerrelationship between diabetes and renal
cell cancer. Most case–control studies re-
ported no association (8,10,11). In the
cohorts of hospitalized diabetic patients,
the incidence rates of renal cell cancer
were higher than in the general popula-
tions (12,13). Two general population
cohort studies found no signiﬁcant asso-
ciation (9,19). Some limitations of prior
studies have hampered interpretation:
samplingprevalentcasesthatarenotideal
for etiologic research when prognosis of
outcome is related to exposure (8,10,11),
lack of generalizability (12,13), relatively
short duration of follow-up given the
slow proliferation and unknown latency
of renal cell cancer (9,13), and failure to
update diabetes status during follow-up
(9,19).
Several underlying mechanisms might
explainthelinkbetweendiabetesandrenal
cell cancer. The ﬁrst mechanism is hyper-
insulinemia in type 2 diabetes. Insulin acts
as a growth factor for tumor cell prolifer-
ation and stimulates IGF-1 production,
which also plays a role in carcinogenesis
(2,4,20). Growth factors might be impor-
tant contributors for renal cell cancer de-
velopment given its peculiar biologic
characteristics(i.e.,spontaneousregression
of metastatic lesions after primary tumor
excision) (21) and laboratory evidence
(22). Second, hyperglycemia may affect
carcinogenesis,sinceincreasedglucoseme-
tabolismisoneofthecentralcharacteristics
ofmalignanttissues(4,23).Third,renalhy-
pertrophy, which develops in the earlier
courseofdiabetes,mighthaveimplications
incarcinogenesis,althoughpathogenicsig-
niﬁcance of this mechanical change is un-
clear(12).Finally,inﬂammatorycytokines,
reactive oxygen, and lipid peroxidation are
other possible mechanisms.
This study supports hyperinsuline-
mia as a plausible mechanism of renal cell
cancer development with some evidence.
First, comorbidity of obesity, hyperten-
sion, and type 2 diabetes elevated the risk
of renal cell cancer dose dependently. All
these conditions are the components of
metabolic syndrome, and insulin resis-
tanceisunderlyingpathophysiology(20).
Sinceindividualswithmultiplemetabolic
components are more closely related to
hyperinsulinemia, our results support
the insulin mechanism. Moreover, obese
diabetic women had almost twofold
higher risk of renal cell cancer than obese
nondiabetic women, but the risk was not
different between obese nondiabetic and
nonobese nondiabetic women. This ﬁnd-
ing suggests that metabolic derangement
Figure1—Combinedeffectsoftype2diabetes,obesity,andhypertensionontheriskofrenalcellcancer
intheNurses’HealthStudy,1976–2008.Comorbidconditionsincludeobesity(BMI$30kg/m
2),history
ofhypertension,andtype2diabetes.HRswerederivedfromCoxproportionalmodelsadjustedforagein
months,BMI(kg/m
2,continuous),history ofhypertension,smoking(statusandpack-years),andparity
(nulliparous, 1–2, 3, 4, 51 children) as appropriate. Ptrend values are from two-sided Wald tests for
linear trend. T2D, type 2 diabetes; HT, hypertension. *P , 0.01 with each referent of leftmost
category. **P , 0.002.
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tial for cancer development. In addition,
diabetes without obesity may mainly
represent a failure of insulin secretion
rather than insulin resistance, thus the
lackofassociationbetweendiabeteswith-
out obesity and renal cell cancer adds fur-
ther support to the insulin mechanism.
Second, increased risk was observed
during the relatively early years of diabe-
tes, but the risk plateaued in the later
stages. Other recent studies also ob-
served increased risks of colorectal and
breast cancer during the early years of di-
abetes(24,25).Thistime-speciﬁcincidence
pattern appears consistent with the natural
courseofhyperinsulinemiaintype2diabe-
tes.Typically,type2diabetesdevelopsafter
long-term insulin resistance and compen-
satory hyperinsulinemia; then pancreatic
b-cell failure eventually leads to hypoinsu-
linemiaover many years (12,19). Nonethe-
less, considering the small number of cases
ofrenalcellcancerafter15yearsofdiabetes
in this cohort, the lack of association could
be obtained by chance.
Thisstudyhasseverallimitations.First,
detection bias cannot be ignored because
diabeticpatientsaremorelikelytobeunder
enhanced surveillance for kidney compli-
cations. However, exclusion of the cancer
cases within 2 years of diabetes diagnoses
still resulted in a signiﬁcant association.
Second, despite a large cohort size, the
number of cases in some subgroups (i.e.,
duration of diabetes $15 years) was small.
Third,residualconfoundingcouldexist,al-
though we adjusted for most of the impor-
tant confounders. Finally, this study
consisted of women and thus the results
may not be generalized to men.
Strengths of this study include a pro-
spective design and relatively large num-
ber of renal cell cancer cases. To our
knowledge, this cohort provides the lon-
gest follow-up for the largest population
of women in which the association be-
tween diabetes and renal cell cancer has
been evaluated. We ascertained renal cell
cancer with histological evidence. Self-
reports of physician-diagnosed diabetes
were highly accurate according to a val-
idation study (15). This study examined
the risk of renal cell cancer only in the
diagnosed diabeticwomen,butmisclassi-
ﬁcation as a result of undiagnosed diabe-
tes should be low since we updated
diabetes status biennially and the nurses
in this study have a low rate of undiag-
nosed diabetes (15). We also updated the
information on most of the established
risk factors for renal cell cancer.
In conclusion, type 2 diabetes was
independently associated with an elevated
risk of renal cell cancer in this cohort of
women. When combinedwith obesity and
hypertension, the elevated risk of renal cell
cancer ishigh. Future studiesthat focus on
more direct measurement of hyperinsuli-
nemia are warranted.
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